Some HLA alleles have been shown to be associated with susceptibility to cytomegalovirus (CMV) disease incidence in vitro. The objective of this study was to identify correlations between donor HLA allotypes and CMV disease incidence in patients with acute myeloid leukemia who had undergone allogeneic hematopoietic stem cell transplantation (HSCT). Methods and materials we retrospectively analyzed the medical records of 613 donors and recipients with acute myeloid leukemia who had received an allogeneic HSCT from matched sibling (n = 260), unrelated (n = 168), or haploidentical (n = 186) donors, from 2012 to 2017. The HLA‐A, ‐B, ‐C, and ‐DRB1 allotypes in the donors were determined using sequence‐based typing. Overall, CMV disease incidence was significantly associated with three genotype alleles, HLA‐A*30:04:01G, ‐B*51:01:01G, and ‐DRB1*09:01:02G. In the donor CMV IgG seropositive subgroup, CMV disease incidence was significantly associated with HLA‐B*51:01:01G and ‐DRB1*09:01:02G. In the IgG seropositive donors in the unrelated allo‐HSCT subgroup CMV disease incidence was also significantly associated with HLA‐B*51:01:01G. In the CMV seropositive donors in the haploidentical allo‐HSCT subgroup, the incidence of CMV disease was significantly associated with HLA‐A*24:02:01G and ‐DRB1*09:01:02G. HLA‐DRB1*13:02:01G was a protective marker among IgG seropositive donors in the unrelated allo‐HSCT recipient category. Discussion and conclusions The incidence of CMV disease among HSCT recipients varies according to donor HLA alleles and the donor CMV IgG serostatus. Certain donor HLA alleles can be considered to be risk or protective markers. Donors' HLA types and CMV IgG serostatus should be considered in donor selection.

中文翻译：

---

特定的供体HLA同种异型可预测急性髓性白血病中巨细胞病毒疾病的风险。

一些HLA等位基因已显示与体外巨细胞病毒（CMV）疾病易感性相关。这项研究的目的是确定同种异体造血干细胞移植（HSCT）的急性髓细胞性白血病患者中供体HLA同种异型与CMV疾病发生率之间的相关性。方法和材料，我们回顾性分析了613例急性髓性白血病的供者和接受者的病历，这些接受者来自同胞（n = 260），不相关（n = 168）或单倍体（n = 186）的同种异体HSCT 2012年至2017年。使用基于序列的分型确定供体中的HLA-A，-B，-C和-DRB1异型。总体而言，CMV疾病发病率与三个基因型等位基因HLA-A * 30：04：01G显着相关，‐ B * 51：01：01G和‐DRB1 * 09：01：02G。在供体CMV IgG血清阳性亚组中，CMV疾病发生率与HLA‐B * 51：01：01G和‐DRB1 * 09：01：02G显着相关。在无关的all-HSCT亚组的IgG血清阳性供体中，CMV疾病的发生率也与HLA-B * 51：01：01G显着相关。在单倍异基因-HSCT亚组的CMV血清反应阳性供体中，CMV疾病的发生与HLA-A * 24：02：01G和‐DRB1 * 09：01：02G显着相关。HLA‐DRB1 * 13：02：01G在无关的allo-HSCT接受者类别中，IgG是IgG血清阳性供体中的保护性标志。讨论和结论HSCT接受者中CMV疾病的发生率因供体HLA等位基因和供体CMV IgG血清状况而异。某些供体HLA等位基因可以被认为是危险或保护性标志物。选择供体时应考虑供体的HLA类型和CMV IgG血清状态。